2 Suppliers
1 Customers
3 Debt Items
12 Related Chains
Search PGEN in the supply chain database
Create PGEN supply chain alerts
Read PGEN supply chain intel
ORANGE supply chain
NVIDIA Corporation supply chain
Amazon.com, Inc. supply chain
Johnson & Johnson supply chain
Suppliers 2
Clients 1
Debt 3
Acquisitions 0
Ownership 1
Secondary 12
Precigen, Inc. Suppliers
Ticker Name Confidence Evidence
CLLS
Cellectis S.A.
72%
ions will be subject to FCPA, which prohibits, among other things, United States companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, …
CLLS
Cellectis S.A.
72%
Reciprocal relationship from CLLS graph: Reciprocal relationship from PGEN graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from PGEN graph: Reciprocal relationship from CLLS g…
Precigen, Inc. Customers
Ticker Name Confidence Evidence
EXEMPLAR
EXEMPLAR
92%
Service revenues, which were all generated by Exemplar.
Precigen, Inc. Debt Obligations
Instrument Description Confidence Evidence
PGEN-DEBT-11754
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
PGEN-DEBT
Debt stack $98.2M
90%
Market cache reports total debt of $98.2M.
PGEN-DEBT-11753
Warrants outstanding: 190060000
90%
xbrl warrant detail from xbrl 2025-12-31.
Precigen, Inc. Acquisitions
No acquisitions on record No completed or pending acquisitions found in our database for Precigen, Inc..
Precigen, Inc. Ownership
Holder Name Confidence Evidence
PGEN-OWNER-PATIENT-CAPITAL-MANAGEMENT-LLC
Patient Capital Management, LLC
90%
13F overlay lists Patient Capital Management, LLC as top holder; 205 tracked holders.
Precigen, Inc. Extended Supply Chain Network
Ticker Name Chain Index Hops Relationship Types
CLLS
Cellectis S.A.
100.00
1
['supplier']
DTIL
Precision BioSciences, Inc.
50.00
2
AZN
AstraZeneca PLC
50.00
2
ALLO
Allogene Therapeutics, Inc.
50.00
2
BMY
Bristol-Myers Squibb Company
50.00
2
BMYMP
Bristol-Myers Squibb Co
50.00
2
TKPHF
Takeda Pharmaceutical Company Limited
50.00
2
TMO
Thermo Fisher Scientific Inc.
50.00
2
IOVA
Iovance Biotherapeutics, Inc.
50.00
2
LYEL
Lyell Immunopharma, Inc.
50.00
2
AUTL
Autolus Therapeutics plc
50.00
2
NTLA
Intellia Therapeutics, Inc.
50.00
2